=> file caplus
FILE 'CAPLUS' ENTERED AT 14:30:24 ON 28 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Oct 2004 VOL 141 ISS 18
FILE LAST UPDATED: 27 Oct 2004 (20041027/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 22 SEA FILE=REGISTRY SSS FUL L1
L4 3 SEA FILE=CAPLUS L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:346231 CAPLUS
DOCUMENT NUMBER: 141:71490
TITLE: Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor
AUTHOR(S): Kim, Dae-Kee; Kim, Joonseop; Park, Hyun-Ju
CORPORATE SOURCE: College of Pharmacy, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-gu, Seoul, 120-750, S. Korea
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(10), 2401-2405
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:71490
GI



I

AB A series of 2-pyridinyl-[1,2,3]triazoles have been synthesized and evaluated for their ALK5 inhibitory activity in the luciferase reporter assays. Quinoxalinyl-substituted 2-pyridinyl-[1,2,3]triazole I showed significant ALK5 inhibition (SBE-luciferase activity, 25%; p3TP-luciferase activity, 17%) at a concentration of 5 μM that is comparable to that of SB-431542 (SBE-luciferase activity, 21%; p3TP-luciferase activity, 12%), but weak p38α MAP kinase inhibition (13%) at a concentration of 10 μM that is much lower than that of SB-431542 (54%).

IT **710946-96-6P 710946-97-7P 710946-98-8P**
710946-99-9P 710947-08-3P 710947-09-4P
710947-10-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor)

RN 710946-96-6 CAPLUS

CN Benzonitrile, 4-[[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710946-97-7 CAPLUS

CN Benzonitrile, 4-[[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710946-98-8 CAPLUS
CN Benzonitrile, 4-[[4-(2-pyridinyl)-5-(6-quinoxalinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710946-99-9 CAPLUS
CN Benzonitrile, 4-[[4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-08-3 CAPLUS
CN Benzonitrile, 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



RN 710947-09-4 CAPLUS
CN Benzonitrile, 4-[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



RN 710947-10-7 CAPLUS
CN Benzonitrile, 4-[4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



IT **710947-02-7P 710947-03-8P 710947-04-9P**
710947-05-0P 710947-13-0P 710947-14-1P
710947-15-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor)

RN 710947-02-7 CAPLUS
CN Benzamide, 4-[[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-03-8 CAPLUS
CN Benzamide, 4-[[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-04-9 CAPLUS
CN Benzamide, 4-[[4-(2-pyridinyl)-5-(6-quinoxalinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-05-0 CAPLUS
CN Benzamide, 4-[[4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-2H-1,2,3-triazol-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 710947-13-0 CAPLUS
CN Benzamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



RN 710947-14-1 CAPLUS
CN Benzamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



RN 710947-15-2 CAPLUS
CN Benzamide, 4-[4-(6-methyl-2-pyridinyl)-5-(6-quinoxalinyl)-2H-1,2,3-triazol-2-yl]- (9CI) (CA INDEX NAME)



IT **710946-91-1P 710946-92-2P 710946-93-3P**
710946-94-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor β1 type 1 receptor)
RN 710946-91-1 CAPLUS
CN Pyridine, 2-[5-(1,3-benzodioxol-5-yl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 710946-92-2 CAPLUS
CN Pyridine, 2-[5-(1,3-benzodioxol-5-yl)-2H-1,2,3-triazol-4-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 710946-93-3 CAPLUS
CN Quinoxaline, 6-[5-(2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 710946-94-4 CAPLUS
CN Quinoxaline, 6-[5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:267243 CAPLUS
DOCUMENT NUMBER: 140:287414
TITLE: Preparation of 2-(triazolyl)pyridines and related compounds as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.
INVENTOR(S): Blumberg, Laura Cook; Munchhof, Michael John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004026307	A1	20040401	WO 2003-IB3825		20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2004110798	A1	20040610	US 2003-667183		20030917
PRIORITY APPLN. INFO.:			US 2002-412079P	P	20020918
			US 2003-484535P	P	20030702

OTHER SOURCE(S): MARPAT 140:287414
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I, II and III [R1 = (un)saturated aromatic, monocyclic, bicyclic, etc.; R2 = (R3)s; R3 = H, halo, halo-alkyl, etc.; s = 1-5; R4 = H, halo, alkenyl, etc.] and their pharmaceutically acceptable salts were prepared For example, [3+2] cycloaddn. of azidotrimethylsilane to alkyne IV e.g., prepared from 6-bromo-3-methyl-1,2,4-triazolo[4,3-a]pyridine in 3-steps, afforded triazole V in 39% yield. In β1-transforming growth factors kinase assay, triazole V exhibited an IC50 value of 58 nM. Of note, triazoles I, II and III also possess differential activity, i.e. are selective for β1-TGF over β2-TGF and β3-TGF. Compds. I, II and III are claimed useful for the treatment of TGF-related disease states including cancer and fibrotic diseases.

IT **676169-95-2P**, 6-[5-(6-Methylpyridin-2-yl)-2H-[1,2,3]triazol-4-yl]quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(triazolyl)pyridines and related compds. as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.)

RN 676169-95-2 CAPLUS
CN Quinazoline, 6-[5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:391710 CAPLUS
DOCUMENT NUMBER: 136:401764
TITLE: Preparation of pyridyl-substituted triazoles as TGF inhibitors
INVENTOR(S): Gaster, Laramie Mary; Harling, John David; Heer, Jag Paul; Heightman, Thomas Daniel; Payne, Andrew Hele
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002040476	A1	20020523	WO 2001-GB5036		20011115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002014163	A5	20020527	AU 2002-14163		20011115
EP 1335916	A1	20030820	EP 2001-982621		20011115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004517069	T2	20040610	JP 2002-543486		20011115
US 2004152738	A1	20040805	US 2004-416680		20040322
PRIORITY APPLN. INFO.:			GB 2000-27987	A	20001116
			WO 2001-GB5036	W	20011115

OTHER SOURCE(S): MARPAT 136:401764
GI



I



II

AB The title compds. [I; R1 = (un)substituted naphthyl, Ph, or Ph fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N; R2 = H, alkyl, alkoxy, etc.; two of X1-X3 = N and the other is NR3 (wherein R3 = H, alkyl, cycloalkyl, etc.)] and their pharmaceutically acceptable salts, useful for the treatment of a disease mediated by the ALK5 receptor in mammals, were prepared Thus, treatment of 5-(6-methylpyridin-2-ylethynyl)-benzo[1,2,5]thiadiazole (preparation given) with TMSN3 afforded 75% II. The compds. I generally show ALK5 receptor modulator activity having IC50 of 0.0001-10 μM.

IT **428817-38-3P 428817-43-0P 428817-44-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridyl-substituted triazoles as TGF inhibitors)

RN 428817-38-3 CAPLUS

CN 2,1,3-Benzothiadiazole, 5-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 428817-43-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 428817-44-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-methyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall
FILE 'USPATFULL' ENTERED AT 14:31:10 ON 28 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:31:10 ON 28 OCT 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 22 SEA FILE=REGISTRY SSS FUL L1
L5 2 SEA L3

=> d l5 1-2 ibib abs hitstr

L5 ANSWER 1 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2004:197432 USPATFULL
TITLE: Pyridyl-substituted triazoles as tgf inhibitors
INVENTOR(S): Gaster, Laramie Mary, Harlow Essex, UNITED KINGDOM
Harling, John David, Harlow Essex, UNITED KINGDOM
Heer, Jag Paul, Harlow Essex, UNITED KINGDOM
Heightman, Thomas Daniel, Harlow Essex, UNITED KINGDOM
Payne, Andrew Hele, Harlow Essex, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004152738	A1	20040805	
APPLICATION INFO.:	US 2004-416680	A1	20040322	(10)
	WO 2001-GB5036		20011115	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-27987	20001116

10/667,183

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pyridyl substituted triazoles of formula (I) ##STR1##

wherein R.sub.1 is naphthyl or phenyl optionally substituted with one or more substituents selected from the group consisting of halo, --O--C.sub.1-6alkyl, --S--C.sub.1-6alkyl, C.sub.1-6alkyl, C.sub.1-6haloalkyl, --O--(CH.sub.2).sub.n-Ph, --S--(CH.sub.2).sub.n-Ph, cyano, phenyl, and CO.sub.2R, wherein R is hydrogen or C.sub.1-6alkyl, and n is 0, 1, 2 or 3; or R.sub.1 is phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C.sub.1-6 alkyl;

R.sub.2 is H, C.sub.1-6alkyl, C.sub.1-6alkoxy, phenyl, NH(CH.sub.2).sub.n-Ph, NH--C.sub.1-6alkyl, halo, CN, NO.sub.2, CONHR and SO.sub.2NHR;

two of X.sub.1, X.sub.2 and X.sub.3 are N and the other is NR.sub.3 wherein R.sub.3 is hydrogen, C.sub.1-6alkyl, C.sub.3-7cycloalkyl, --(CH.sub.2).sub.p--CN, --(CH.sub.2).sub.p--CO.sub.2H, --(CH.sub.2).sub.p--CONHR.sub.4R.sub.5, --(CH.sub.2).sub.pCOR.sub.4, --(CH.sub.2).sub.q(OR.sub.6).sub.2,

--(CH.sub.2).sub.pOR.sub.4, --(CH.sub.2).sub.q--CH.dbd.CH--CN, --(CH.sub.2).sub.q--CH.dbd.CH--CO.sub.2H, --(CH.sub.2).sub.p--CH.dbd.CH--CONHR.sub.4R.sub.5, (CH.sub.2).sub.pNHCOR.sub.7 or (CH.sub.2).sub.pNR.sub.8R.sub.9;

R.sub.4 and R.sub.5 are independently hydrogen or C.sub.1-6alkyl;

R.sub.6 is C.sub.1-6alkyl;

R.sub.7 is C.sub.1-7alkyl, or optionally substituted aryl, heteroaryl, arylC.sub.1-6alkyl or heteroarylC.sub.1-6alkyl;

R.sub.8 and R.sub.9 are independently selected from hydrogen, C.sub.1-6alkyl, aryl and arylC.sub.1-6alkyl;

p is 04; and

q is 1-4.

and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **428817-38-3P 428817-43-0P 428817-44-1P**
(preparation of pyridyl-substituted triazoles as TGF inhibitors)
RN 428817-38-3 USPATFULL
CN 2,1,3-Benzothiadiazole, 5-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 428817-43-0 USPATFULL
CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-ethyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



RN 428817-44-1 USPATFULL
CN [1,2,4]Triazolo[1,5-a]pyridine, 6-[2-methyl-5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER:	2004:145125 USPATFULL
TITLE:	Novel triazole compounds as transforming growth factors (TGF) inhibitors
INVENTOR(S):	Munchhof, Michael J., Salem, CT, UNITED STATES Blumberg, Laura C., Waterford, CT, UNITED STATES
PATENT ASSIGNEE(S):	Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004110798	A1	20040610	
APPLICATION INFO.:	US 2003-667183	A1	20030917	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-412079P	20020918	(60)
	US 2003-484535P	20030702	(60)

10/667,183

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel triazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor ("TGF")-β signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **676169-95-2P**, 6-[5-(6-Methylpyridin-2-yl)-2H-[1,2,3]triazol-4-yl]quinazoline
(preparation of 2-(triazolyl)pyridines and related compds. as transforming growth factor (TGF) inhibitors for the treatment of cancer and fibrotic diseases.)

RN 676169-95-2 USPATFULL

CN Quinazoline, 6-[5-(6-methyl-2-pyridinyl)-2H-1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)



=>